<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0907245505
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        REDEX 5 MG F.C.TABLET  
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TADALAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        136.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Al-Taqaddom pharmaceutical Industries " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Al-Taqaddom pharmaceutical Industries 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Al-Taqaddom pharmaceutical Industries 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What Redex&reg; 5 is and what it is used for</strong></p><p><strong>Pharmacotherapeutic group:</strong></p><p><strong>Redex&reg; 5 </strong>contains the active substance tadala_l which belongs to a group of medicines called</p><p>phosphodiesterase type 5 inhibitors. Following sexual stimulation <strong>Redex&reg; 5 </strong>works by helping the</p><p>blood vessels in your penis to relax, allowing the _ow of blood into your penis. _e result of this is</p><p>improved erectile function. <strong>Redex&reg; 5 </strong>will not help you if you do not have erectile dysfunction.</p><p><strong>_eraputic indications:</strong></p><p><strong>Redex&reg; 5 mg is used to treat adult men with:</strong></p><p><strong>- Erectile dysfunction. </strong>_is is when a man cannot get, or keep a hard, erect penis suitable for sexual</p><p>activity. <strong>Redex&reg; 5 </strong>has been shown to signi_cantly improve the ability of obtaining a hard erect penis</p><p>suitable for sexual activity. Following sexual stimulation <strong>Redex&reg; 5 </strong>works by helping the blood vessels</p><p>in your penis to relax, allowing the _ow of blood into your penis. _e result of this is improved</p><p>erectile function. <strong>Redex&reg; 5 </strong>will not help you if you do not have erectile dysfunction. It is important to</p><p>note that <strong>Redex&reg; 5 </strong>for the treatment of erectile dysfunction does not work if there is no sexual</p><p>stimulation. You and your partner will need to engage in foreplay, just as you would if you were not</p><p>taking a medicine for erectile dysfunction.</p><p><strong>-Urinary symptoms associated with a common condition called benign prostatic hyperplasia. </strong>_is</p><p>is when the prostate gland gets bigger with age. Symptoms include di_culty in starting to pass water,</p><p>a feeling of not completely emptying the bladder and a more frequent need to pass water even at</p><p>night. <strong>Redex&reg; 5 </strong>improves blood _ow to, and relaxes the muscles of, the prostate and bladder which</p><p>may reduce symptoms of benign prostatic hyperplasia. <strong>Redex&reg; 5 </strong>has been shown to improve these</p><p>urinary symptoms as early as 1-2 weeks after starting treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. What you need to know before you take Redex&reg;.</strong></p><p><strong>Do not take Redex&reg; 5 if you:</strong></p><p>- are allergic to tadala_l or any of the other ingredients of this medicine.</p><p>- are taking any form of organic nitrate or nitric oxide donors such as amyl nitrite. _is is a group of</p><p>medicines (&ldquo;nitrates&rdquo;) used in the treatment of angina pectoris (&ldquo;chest pain&rdquo;). <strong>Redex&reg; 5 </strong>has been</p><p>shown to increase the e_ects of these medicines. If you are taking any form of nitrate or are unsure</p><p>tell your doctor.</p><p>- have serious heart disease or recently had a heart attack within the last 90 days.</p><p>- recently had a stroke within the last 6 months.</p><p>- have low blood pressure or uncontrolled high blood pressure.</p><p>- ever had loss of vision because of non-arteritic anterior ischemic optic neuropathy (NAION), a</p><p>condition described as &ldquo;stroke of the eye&rdquo;.</p><p>- are taking riociguat. _is drug is used to treat pulmonary arterial hypertension (i.e., high blood</p><p>pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure</p><p>in the lungs secondary to blood clots). PDE5 inhibitors, such as <strong>Redex&reg; 5</strong>, have been shown to</p><p>increase the hypotensive e_ects of this medicine. If you are taking riociguat or are unsure tell your</p><p>doctor.</p><p><strong>Take special care with Redex&reg; 5</strong></p><p>Talk to your doctor before taking <strong>Redex&reg; 5</strong>.</p><p>Be aware that sexual activity carries a possible risk to patients with heart disease because it puts an</p><p>extra strain on your heart. If you have a heart problem you should tell your doctor.</p><p>Since benign prostatic hyperplasia and prostate cancer may have the same symptoms, your doctor will</p><p>check you for prostate cancer before starting treatment with <strong>Redex&reg; 5 </strong>for benign prostatic</p><p>hyperplasia. <strong>Redex&reg; 5 </strong>does not treat prostate cancer.</p><p><strong>Before taking the tablets, tell your doctor if you have:</strong></p><p>- sickle cell anaemia (an abnormality of red blood cells).</p><p>- multiple myeloma (cancer of the bone marrow).</p><p>- leukaemia (cancer of the blood cells).</p><p>- any deformation of your penis.</p><p>- a serious liver problem.</p><p>- a severe kidney problem.</p><p><strong>It is not known if Redex&reg; 5 is e_ective in patients who have had:</strong></p><p>- pelvic surgery.</p><p>- removal of all or part of the prostate gland in which nerves of the prostate are cut (radical</p><p>non-nerve-sparing prostatectomy).</p><p>If you experience sudden decrease or loss of vision, stop taking <strong>Redex&reg; 5 </strong>and contact your doctor</p><p>immediately.</p><p><strong>Children and adolescents</strong></p><p><strong>Redex&reg; 5 </strong>is not intended for use by children and adolescents under the age of 18.</p><p><strong>Taking other medicines</strong></p><p>Please tell your pharmacist or doctor if you are taking or have recently taken any other medicines.</p><p>_is includes medicines that you can buy without a prescription, including herbal medicines. _is is</p><p>because <strong>Redex&reg; 5 </strong>can a_ect the way that some other medicines work and some other medicines can</p><p>a_ect the way that <strong>Redex&reg; 5 </strong>works. Do not take <strong>Redex&reg; 5 </strong>if you are already taking nitrates.</p><p><strong>In particular, tell your pharmacist or doctor if you are taking:</strong></p><p>- an alpha blocker (used to treat high blood pressure or urinary symptoms associated with benign</p><p>prostatic hyperplasia).</p><p>- other medicines to treat high blood pressure.</p><p>- riociguat.</p><p>- a 5- alpha reductase inhibitor (used to treat benign prostatic hyperplasia).</p><p>- medicines such as ketoconazole tablets (to treat fungal infections) and protease inhibitors for</p><p>treatment of AIDS or HIV infection.</p><p>- phenobarbital, phenytoin and carbamazepine (anticonvulsant medicines).</p><p>- rifampicin, erythromycin , clarithromycin or itraconazole.</p><p>- other treatments for erectile dysfunction.</p><p><strong>Taking Redex&reg; 5 with food and drink</strong></p><p>You may take <strong>Redex&reg; 5 </strong>with or without food.</p><p>Drinking alcohol may a_ect your ability to get an erection. Drinking alcohol may temporarily lower</p><p>your blood pressure. If you have taken or are planning to take <strong>Redex&reg; 5</strong>, avoid excessive drinking</p><p>(blood alcohol level of 0.08% or greater), since this may increase the risk of dizziness when standing</p><p>up.</p><p>Grapefruit juice may a_ect how well <strong>Redex&reg; 5 </strong>will work and should be taken with caution. Talk to</p><p>your doctor for further information.</p><p><strong>Pregnancy and breast-feeding: Redex&reg; 5 </strong>is not intended for use by women.</p><p><strong>Fertility : </strong>When dogs were treated there was reduced sperm development in the testes. A reduction</p><p>in sperm was seen in some men. _ese e_ects are unlikely to lead to a lack of fertility.</p><p><strong>Driving and using machines</strong></p><p>Check carefully how you react to the medicines before driving or using any machinery, because some</p><p>men taking <strong>Redex&reg; 5 </strong>in clinical studies have reported dizziness.</p><p><strong>Important information about some of the ingredients of Redex&reg; 5</strong></p><p><strong>Redex&reg; 5 </strong>contains lactose. If you have been told by your doctor that you have an intolerance to some</p><p>sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3. How to take Redex&reg; 5</strong></p><p>Always take <strong>Redex&reg; 5 </strong>exactly as your doctor has told you. You should check with your doctor or</p><p>pharmacist if you are not sure.</p><p><strong>Redex&reg; 5 </strong>tablets are for oral use. Swallow the tablet whole with some water.</p><p>It is important to note that <strong>Redex&reg; 5 </strong>does not work if there is no sexual stimulation. You and your</p><p>partner will need to engage in foreplay, just as you would if you were not taking a medicine for</p><p>erectile dysfunction.</p><p><strong>For the treatment of erectile dysfunction</strong></p><p>_e recommended dose is one 5 mg tablet taken once a day at approximately the same time of the</p><p>day. Your doctor may adjust the dose to 2.5 mg based on your response to <strong>Redex&reg; 5</strong>. _is will be</p><p>given as a 2.5mg tablet.</p><p>Do not take <strong>Redex&reg;5 </strong>more than once a day.</p><p>When taken once a day <strong>Redex&reg; 5 </strong>allows you to obtain an erection, when sexually stimulated, at any</p><p>time point during the 24 hours of the day. Once a day dosing of <strong>Redex&reg; 5 </strong>may be useful to men who</p><p>anticipate having sexual activity two or more times per week. It is important to note that <strong>Redex&reg; 5</strong></p><p>does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay,</p><p>just as you would if you were not taking a medicine for erectile dysfunction.</p><p>Drinking alcohol may a_ect your ability to get an erection and may temporarily lower your blood</p><p>pressure.</p><p><strong>For the treatment of benign prostatic hyperplasia</strong></p><p>_e dose is one 5 mg tablet taken once a day at approximately the same time of the day. If you have</p><p>benign prostatic hyperplasia and erectile dysfunction, the dose remains one 5 mg tablet taken once a</p><p>day. Do not take <strong>Redex&reg; 5 </strong>more than once a day.</p><p><strong>If you take more Redex&reg; 5 than you should</strong></p><p>Contact your doctor. You may experience side e_ects described in possible side e_ects section.</p><p><strong>If you forget to take Redex&reg; 5</strong></p><p>Take your dose as soon as you remember but do not take a double dose to make up for a forgotten</p><p>tablet. You should not take <strong>Redex&reg; 5 </strong>more than once a day.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. Possible side e_ects</strong></p><p>Like all medicines, this medicine can cause side e_ects, although not everybody gets them. _ese</p><p>e_ects are normally mild to moderate in nature.</p><p>In this lea_et, when a side e_ect is described as &ldquo;very common&rdquo; this means that it has been reported</p><p>in at least 1 in 10 patients taking the medicine. When a side e_ect is described as &ldquo;common&rdquo; this</p><p>means that it has been reported in more than 1 in every 100 patients but less than 1 in every 10</p><p>patients. When a side e_ect is described as &ldquo;uncommon&rdquo;, this means it has been reported in more</p><p>than 1 in every 1,000 patients, but less than 1 in every 100 patients. When a side e_ect is described as</p><p>&ldquo;rare&rdquo;, this means it has been reported in more than 1 in every 10,000 patients, but less than 1 in</p><p>every 1,000 patients.</p><p>If you experience any of the following side e_ects stop using the medicine and seek medical help</p><p>immediately:</p><p>- allergic reactions including rashes (frequency uncommon).</p><p>- chest pain - do not use nitrates but seek immediate medical assistance (frequency uncommon). -</p><p>prolonged and possibly painful erection after taking tadala_l (frequency rare). If you have such an</p><p>erection, which lasts continuously for more than 4 hours you should contact a doctor immediately.</p><p>- sudden loss of vision (frequency rare).</p><p><strong>Other side e_ects have been reported:</strong></p><p><strong>Common</strong></p><p>- headache, back pain, muscle aches, pain in arms and legs, facial _ushing, nasal congestion,</p><p>indigestion and re_ux.</p><p><strong>Uncommon</strong></p><p>- dizziness, stomach ache, blurred vision, eye pain, increased sweating, di_culty in breathing, penile</p><p>bleeding, presence of blood in semen and/or urine, pounding heartbeat sensation, a fast heart rate,</p><p>high blood pressure, low blood pressure, nose bleeds and ringing in the ears.</p><p><strong>Rare</strong></p><p>- fainting, seizures and passing memory loss, swelling of the eyelids, red eyes, sudden decrease or loss</p><p>of hearing and hives (itchy red welts on the surface of the skin).</p><p>Heart attack and stroke have also been reported rarely in men taking tadala_l. Most of these men had</p><p>known heart problems before taking this medicine.</p><p>Partial, temporary, or permanent decrease or loss of vision in one or both eyes has been rarely</p><p>reported.</p><p>Some additional rare side e_ects have been reported in men taking tadala_l that were not seen in</p><p>clinical trials. _ese include: -</p><p>migraine, swelling of the face, serious allergic reaction which causes swelling of the face or throat,</p><p>serious skin rashes, some disorders a_ecting blood _ow to the eyes, irregular heartbeats, angina and</p><p>sudden cardiac death.</p><p>_e side e_ects dizziness and diarrhoea have been reported more frequently in men over 75 years of</p><p>age taking tadala_l.</p><p>If any of the side e_ects gets serious, or if you notice any side e_ects not listed in this lea_et, please</p><p>tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. How to store Redex&reg; 5</strong></p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Do not use <strong>Redex&reg; 5 </strong>after the expiry date which is stated on the carton and blister after &lsquo;EXP&rsquo;. _e</p><p>expiry date refers to the last day of that month.</p><p>Store in the original package in order to protect from moisture.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to</p><p>dispose of medicines no longer required. _ese measures will help to protect the environment.</p><p><strong>6. Further information</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Redex&reg; 5 contains</strong></p><p>_e active substance is tadala_l. Each _lm coated tablet contains 5 mg of tadala_l.</p><p>_e other ingredients are: Lactose Monohydrate, Croscarmellose Sodium, Microcrystalline Cellulose,</p><p>Sodium Lauryl sulfate, Povidone K30, Magnesium Stearate, Yellow Iron Oxide &amp; Opadry II white.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Redex® 5 looks like and contents of the pack
Redex® 5 is a yellow _lm coated tablet, almond shaped, biconvex engraved with ''TQ" on one side
and plain on the other side.
Redex® 5 is supplied in blister packs of 30 _lm coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong><br />Al-Taqaddom Pharmaceutical Industries.<br />Almwaqqar &ndash; Amman, Jordan<br />Tel.: +962-6-4050092 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Fax: +962-6-4050091<br />P.O. Box: 1019 Amman 11947 Jordan&nbsp;<br />Email: info@tqpharma.com<br />This leaflet was last approved in 09/ 2016; version number 0<br /><strong>To report any side effect(s):<br />Saudi Arabia:</strong><br />National Pharmacovigilance and Drug Safety Center (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />Email: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br /><strong>Other GCC States:</strong> Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 09/ 2016; version number 0
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1 </strong><strong>ما هو ريديكس&nbsp; 5 ملجم و ما هي دواعي استعماله</strong></p><p dir="RTL"><strong>المجموعة العلاجية</strong><strong>: </strong></p><p dir="RTL">يحتوي ريديكس 5 ملجم على المادة الفعالة تادالافيل و التي تنتمي إلى مجموعة من الأدوية تسمى مثبطات إنزيم فوسفوديستريز نوع 5. يعمل ريديكس 5 ملجم بعد التحفيز الجنسي عن طريق المساعدة في إسترخاء الأوعية الدموية في القضيب، والسماح بتدفق الدم إلى القضيب. ونتيجة لهذا يتم تحسين وظيفة الإنتصاب. لن يساعدك ريديكس 5 ملجم إذا لم يكن لديك مشاكل في الانتصاب.</p><p dir="RTL"><strong>الاستطبابات</strong><strong>:</strong></p><p dir="RTL"><strong>يستعمل ريديكس 5 ملجم لعلاج الرجال البالغين</strong><strong>:</strong></p><p dir="RTL">عدم القدرة على الإنتصاب: هذا عندما لا يمكن للرجل الحصول، أو الاحتفاظ بصلابة قضيب مناسبة للنشاط الجنسي. أظهر <strong>ريديكس</strong> 5 ملجم تحسين القدرة على حصول الرجل على صلابة قضيب مناسبة للنشاط الجنسي بشكل كبير. يعمل <strong>ريديكس</strong> 5 ملجم عن طريق مساعدة الأوعية الدموية في القضيب على الاسترخاء، وبالتالي السماح لتدفق الدم إلى القضيب و ذلك بعد التحفيز الجنسي. ونتيجة لهذا يحسن وظيفة الانتصاب. لن يساعدك <strong>ريديكس</strong> 5 ملجم إذا لم يكن لديك مشاكل في الإنتصاب. من المهم أن تـلاحظ أن <strong>ريديكس</strong> 5 ملجم لا يعمل إذا لم يكن هناك تحفيز جنسي. انت وشريكك بحاجة إلى الانخراط في المداعبة، تماماً كما لو كنت لم تتـناول دواء لعدم القدرة على الإنتصاب.</p><p><strong>الأعراض البولية المصاحبة للحالة الشائعة المسماة تضخم البروستات الحميد,</strong> هذا يحصل عندما تتضخم غدة البروستات مع تقدم العمر. وتتضمن الأعراض صعوبة في بدء تمرير البول، شعور بعدم تفريغ المثانة تماما وزيادة تكرار الحاجة للتبول حتى في الليل. يحسن ريديكس 5 ملجم من تدفق الدم الى البروستات, و يرخي عضلات البروستات و المثانة و التي بدورها قد تقلل من اعراض تضخم البروستات الحميد. أظهر ريديكس 5 ملجم تحسن في هذه الأعراض البولية في وقت قصير بعد أسبوع - أسبوعين من بدء العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2 </strong><strong>قبل القيام بتناول أو استعمال ريديكس 5 ملجم</strong></p><p dir="RTL"><strong>لا تتناول ريديكس 5 ملجم اذا</strong><strong>:</strong></p><p dir="RTL">- كنت تعاني من حساسية ضد تادالافيل أو أي من المكونات الأخرى لريديكس 5 ملجم .</p><p dir="RTL">- كنت تأخذ أي شكل من أشكال النترات العضوية أو معطيات أكسيد النيتريك مثل أميل النترات. &quot;النترات&quot; هي مجموعة من الأدوية المستعملة في علاج الذبحة الصدرية. قد تبين أن ريديكس 5 ملجم يزيد من تأثير هذه الأدوية. أخبر طبيبك إذا كنت تأخذ أي شكل من أشكال النترات أو كنت غير متأكد.</p><p dir="RTL">- كنت تعاني من أمراض قلب خطيرة أو أصبت بنوبة قلبية مؤخراً خلال الايام 90 الماضية.</p><p dir="RTL">- أصبت بسكتة دماغية مؤخراً خلال الاشهر 6 الماضية.</p><p dir="RTL">- كنت تعاني من إنخفاض في ضغط الدم أو تعاني من إرتفاع ضغط الدم غير المنضبط.</p><p dir="RTL">- كنت قد أصبت بفقدان الرؤية بسبب اعتلال عصبي بصري دماغي امامي غير شرياني(NAION), و هي حالة توصف &quot;سكته بالعين&quot;.</p><p dir="RTL">- كنت تتناول&nbsp; ريوسيجويت , هو دواء يستخدم لعلاج ارتفاع ضغط الدم الشرياني الرئوي (أي ارتفاع ضغط الدم في الرئتين) وارتفاع ضغط الدم الرئوي الانسدادي التجلطي المزمن (أي ارتفاع ضغط الدم في الرئتين الثانوي لتجلط الدم). أظهرت مثبطات إنزيم فوسفوديستريز النوع الخامس مثل ريديكس 5 ملجم, زيادة التأثير الخافض للضغط لهذا الدواء. اذا كنت تتناول ريوسيجويت او لست متاكدا من ذلك استشر طبيبك.</p><p dir="RTL"><strong>خذ احتياطا مع ريديكس 5 ملجم</strong><strong>:</strong></p><p dir="RTL">تحدث الى طبيبك قبل تناول أقراص <strong>ريديكس</strong> 5 ملجم</p><p dir="RTL">يجب أن تكون على علم بأن النشاط الجنسي ينطوي على مخاطر محتملة للمرضى المصابين بأمراض القلب لأنه يضع ضغطاً إضافياً على قلبك. إذا كان لديك مشكلة في القلب فعليك أن تخبر طبيبك.</p><p dir="RTL">حيث ان تضخم البروستات الحميد و سرطان البروستات قد تكون لهم نفس الأعراض, سيقوم طبيبك بالتحقق من وجود سرطان البروستات قبل بدء علاج&nbsp; تضخم البروستات الحميد باستخدام ريديكس 5 ملجم. ريديكس 5 ملجم لا يعالج سرطان البروستات.</p><p dir="RTL"><strong>قبل أخذك للاقراص, أخبر طبيبك اذا كان لديك</strong><strong> : </strong></p><p dir="RTL">- فقر الدم المنجلي (خلل في خلايا الدم الحمراء).</p><p dir="RTL">- المايلوما المتعددة (سرطان نخاع العظم).</p><p dir="RTL">- لوكيميا (سرطان الدم).&nbsp;</p><p dir="RTL">- أي تشوه في القضيب.</p><p dir="RTL">- مشكلة خطيرة في الكبد.</p><p dir="RTL">- مشكلة خطيرة في الكلى.</p><p dir="RTL"><strong>من غير المعروف ما إذا كان ريديكس 5 ملجم فعال في المرضى الذين</strong><strong>:</strong></p><p dir="RTL">- خضعوا لعملية جراحية في الحوض</p><p dir="RTL">- إستئصلوا كل أو جزء من غدة البروستات, والتي تقطع فيها أعصاب البروستات (استئصال البروستات الجذري غير العصبي).</p><p dir="RTL">- إذا واجهت إنخفاض مفاجئ أو فقدان الرؤية، توقف عن تناول <strong>ريديكس</strong> 5 ملجم وإتصل بطبيبك على الفور.</p><p dir="RTL"><strong>الأطفال و المراهقون</strong></p><p dir="RTL">لا يوصى بإستعمال <strong>ريديكس</strong> 5 ملجم من قبل الأطفال و المراهقين دون سن 18 عاماً.</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">الرجاء اعلام الطبيب او الصيدلي اذا كنت تتناول او قد تناولت مؤخرا اية ادوية اخرى, بما في ذلك الادوية التى تصرف بدون وصفة طبية و الادوية العشبية. وذلك لان <strong>ريديكس</strong> 5 ملجم قد يؤثر على طريقة عمل بعض الادوية او قد تؤثر بعض الادوية على طريقة عمل <strong>ريديكس</strong> 5 ملجم. يجب عدم تناول <strong>ريديكس</strong> 5 ملجم إذا كنت تأخذ النترات.</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي اذا كنت تأخذ بالفعل</strong><strong> : </strong></p><p dir="RTL">- مثبطات&nbsp; مستقبلات ألفا (يستعمل لعلاج إرتفاع ضغط الدم أو الأعراض البولية المصاحبة لتضخم البروستات).</p><p dir="RTL">- أدوية أخرى لعلاج إرتفاع ضغط الدم.</p><p dir="RTL">- ريوسيجويت</p><p dir="RTL">- مثبطات 5 ألفا ريداكتيز ( تستخدم لعلاج تضخم البروستات الحميد)</p><p dir="RTL">- أدوية مثل كيتوكونازول ( لعلاج الالتهابات الفطرية ) ومثبطات إنزيم البروتياز لعلاج عدوى الايدز أو فيروس نقص المناعة المكتسبة.</p><p dir="RTL">- الفينوباربيتال، الفينيتوين وكاربامازيبين (أدوية مضادة للتشنج).</p><p dir="RTL">- ريفامبيسين، اريثروميسين، كلاريثروميسين أو ايتراكونازول.</p><p dir="RTL">- أدوية أخرى لعلاج عدم القدرة على الإنتصاب.</p><p dir="RTL"><strong>تناول ريديكس 5 ملجم مع الطعام و الشراب</strong></p><p dir="RTL">يمكن تناول <strong>ريديكس</strong> 5 ملجم مع أو دون طعام.</p><p dir="RTL">قد يؤثر شرب الكحول على قدرة حصولك على انتصاب.&nbsp; قد يخفض شرب الكحول&nbsp; ضغط الدم بشكل مؤقت. إذا كنت قد تناولت أو خططت لتناول <strong>ريديكس</strong> 5 ملجم فإنه يجب عليك تجنب الإفراط في شرب الكحول (مستوى الكحول في الدم من 0.08٪ أو أعلى)، حيث أن هذا قد يزيد من خطر حدوث الدوخة عند الوقوف.</p><p dir="RTL">قد يؤثر عصير الجريب فروت على فعالية ريديكس 5 ملجم و يجب ان يؤخذ بحذر. تحدث الى طبيبك لمزيد من المعلومات.</p><p dir="RTL"><strong>الحمل و الرضاعة</strong></p><p dir="RTL"><strong>ريديكس</strong> 5 ملجم غير مخصص للاستخدام من قبل النساء.</p><p dir="RTL"><strong>الخصوبة</strong><strong>:</strong></p><p dir="RTL">عندما عولج الكلاب , لوحظ انخفاض في نمو الحيوانات المنوية في الخصيتين. لوحظ تناقص في الحيوانات المنوية لدى بعض الرجال. من غير المرجح ان تؤدي هذه الآثار الى فقدان الخصوبة.</p><p dir="RTL"><strong>القيادة وإستعمال الآليات</strong><strong>: </strong></p><p dir="RTL">تحقق بعناية كيف تتفاعل مع الدواء قبل القيادة او إستعمال الآلات و ذلك لأن بعض الرجال الذين تناولوا ريديكس 5 ملجم في الدراسات السريرية أبلغوا عن حدوث دوخة.&nbsp;</p><p dir="RTL"><strong>معلومات هامة عن بعض المواد في ريديكس 5 ملجم</strong><strong>:</strong></p><p>يحتوي <strong>ريديكس</strong> 5 ملجم على اللاكتوز. إذا أخبرت من قبل طبيبك بأن لديك تعصب لبعض السكريات، إتصل بطبيبك قبل تناول هذا العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>3.&nbsp;</strong><strong>طريقة تناول ريديكس 5 ملجم</strong></p><p dir="RTL">دائما , تناول <strong>ريديكس</strong> 5 ملجم تماما كما اخبرك طبيبك. يجب عليك مراجعة الطبيب أو الصيدلي إذا كنت غير متأكد. تستعمل اقراص <strong>ريديكس</strong> 5 ملجم عن طريق الفم. يجب تناول أقراص <strong>ريديكس</strong> 5 ملجم كاملة مع بعض الماء. من المهم أن تـلاحظ أن ريديكس 5 ملجم لا يعمل إذا لم يكن هناك تحفيز جنسي. انت وشريكك بحاجة إلى الانخراط في المداعبة، تماماً كما لو كنت لم تتـناول دواء لعدم القدرة على الإنتصاب.</p><p dir="RTL"><strong>لعلاج عدم القدرة على الإنتصاب</strong><strong>:</strong></p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من&nbsp; ريديكس 5 ملجم يؤخذ مرة واحدة يوميا, في نفس الوقت تقريبا من اليوم. قد يقوم طبيبك بتعدبل الجرعة لتصبح 2.5 ملجم اعتمادا على استجابتك لجرعة 5 ملجم من <strong>ريديكس</strong>. تعطى على شكل قرص 2.5 ملجم.</p><p dir="RTL">لا تتناول <strong>ريديكس</strong> 5 ملجم أكثر من مرة واحدة يوميا.</p><p dir="RTL">عند أخذ <strong>ريديكس</strong> 5 ملجم مرة واحدة يوميا, فانه يتيح لك الحصول على انتصاب عندما تكون محفز جنسيا عند أي نقطة زمنية خلال الــ 24 ساعة في اليوم. ان جرعة واحدة في اليوم من <strong>ريديكس</strong> 5 ملجم, قد تكون مفيدة للرجال الذين يتوقعون نشاط جنسي مرتين أو أكثر في الأسبوع.</p><p dir="RTL">من المهم أن تـلاحظ أن <strong>ريديكس</strong> 5 ملجم لا يعمل إذا لم يكن هناك تحفيز جنسي. انت وشريكك بحاجة إلى الانخراط في المداعبة، تماماً كما لو كنت لم تتـناول دواء لعدم القدرة على الإنتصاب.</p><p dir="RTL">قد يؤثر شرب الكحول على قدرة حصولك على انتصاب.&nbsp; شرب الكحول قد يخفض ضغط الدم بشكل مؤقت.</p><p dir="RTL"><strong>لعلاج تضخم البروستات الحميد</strong><strong> </strong></p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من <strong>ريديكس</strong> 5 ملجم , تؤخذ مرة واحدة يوميا في نفس الوقت تقريبا من اليوم. اذا كان لديك تضخم البروستات الحميد مصاحبا لعدم القدرة على الانتصاب, تبقى الجرعة قرص واحد من <strong>ريديكس</strong> 5 ملجم مرة واحدة يوميا. لا تاخذ <strong>ريديكس</strong> 5 ملجم أكثر من مرة واحدة يوميا.</p><p dir="RTL"><strong>اذا تناولت ريديكس 5 ملجم أكثر مما يجب</strong></p><p dir="RTL">اتصل بطبيبك. قد تعاني من الآثار الجانبية المذكورة في بند الآثار الجانبية المحتملة.</p><p dir="RTL"><strong>إذا نسيت تناول&nbsp; أقراص ريديكس 5 ملجم</strong></p><p dir="RTL">تناول جرعتك حين تذكرها و لكن لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية. يجب عدم تناول <strong>ريديكس</strong> 5 ملجم أكثر من مرة واحدة يوميا.</p><p dir="RTL">اذا كانت لديك أي اسئلة أخرى حول طريقة استعمال هذا الدواء, اسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>4 </strong><strong>الآثار الجانبية المحتملة</strong></p><p dir="RTL">مثل كل الأدوية, قد يسبب ريديكس 5 ملجم أعراض جانبية, وان كانت لا تصيب الجميع.</p><p dir="RTL">في هذه النشرة عندما يوصف أحد الأعراض الجانبية بأنه (شائع جدا) فهذا يعني أنه ظهر في 1 على الأقل من كل 10 مرضى تناولوا هذا الدواء, و عندما يوصف بأنه (شائع) فهذا يعني أنه ظهر في أكثر من 1 من كل 100 مريض تناولوا هذا الدواء, ولكن أقل من 1 من كل 10 مرضى, و عندما يوصف بأنه (غير شائع) فهذا يعني أنه ظهر في أكثر من 1 من كل 1000 مريض تناولوا هذا الدواء, و لكن أقل من 1 من كل 100 مريض, و عندما يوصف بأنه (نادر) فهذا يعني أنه ظهر في أكثر من 1 من كل 10000 مريض تناولوا هذا الدواء, ولكن أقل من 1 من كل1000 مريض.</p><p dir="RTL">اذا عانيت من اي من الآثار الجانية التالية, أوقف استخدام العلاج و اطلب المساعدة الطبية على الفور:</p><p dir="RTL">- تفاعلات الحساسية بما في ذلك الطفح الجلدي (آثار جانبية غير شائعة).</p><p dir="RTL">- ألم في الصدر - لا تستخدم النترات ولكن اطلب مساعدة طبية فورية (آثار جانبية غير شائعة).</p><p dir="RTL">- الانتصاب لفترات طويلة، وربما مؤلمة بعد تناول <strong>تادالافيل</strong> (نادر الحدوث).</p><p dir="RTL">&nbsp; إذا كان لديك مثل هذا الانتصاب، والذي يستمر بشكل مستمر لأكثر من 4 ساعات يجب عليك الاتصال بالطبيب فورا.</p><p dir="RTL">- فقدان مفاجئ للرؤية (نادر الحدوث).</p><p dir="RTL"><strong>تم الإبلاغ عن آثار جانبية أخرى</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة</strong></p><p dir="RTL">صداع ,آلام الظهر، آلام في العضلات، الم في الذراعين والساقين, إحمرار الوجه، إحتقان الأنف، عسر هضم, ارتجاع.</p><p dir="RTL"><strong>غير شائعة</strong></p><p dir="RTL">الدوخة، آلام المعدة، عدم وضوح الرؤية، آلام في العين، زيادة التعرق، صعوبة في التنفس، نزف القضيب، وجود دم في السائل المنوي و / أو البول، شعور بقوة ضربات القلب، سرعة دقات القلب، ارتفاع ضغط الدم، وانخفاض ضغط الدم، نزيف الأنف, طنين في الأذنين.</p><p dir="RTL"><strong>نادرة</strong></p><p dir="RTL">اغماء، نوبات عصبية و فقدان ذاكرة عابر، تورم في الجفون, احمرار في العينين، انخفاض أو فقدان السمع المفاجئ, الشرى (بقع حمراء وحكة على سطح الجلد).</p><p dir="RTL">ونادرا ما تم الإبلاغ عن نوبات قلبية وسكتة دماغية في الرجال الذين يتناولون <strong>تادالافيل</strong>. وكان معظم هؤلاء الرجال قد عانوا من مشاكل في القلب قبل تناول هذا الدواء.</p><p dir="RTL">ونادرا ما تم الابلاغ عن نقصان&nbsp; أو فقدان جزئي، مؤقت أو دائم للبصر في إحدى أو كلتا العينين.</p><p dir="RTL">وقد تم الإبلاغ عن بعض الآثار الجانبية الاضافية النادرة الحدوث والتي لم تشاهد في التجارب السريرية, في الرجال الذين يتناولون <strong>ريديكس</strong> وتشمل هذه الآثار:</p><p dir="RTL">- الصداع النصفي، تورم في الوجه، تفاعلات الحساسية الخطرة التي يؤدي الى تورم في الوجه أو الحلق، طفح جلدي خطر, بعض الاضطرابات التي تؤثر على تدفق الدم إلى العينين، عدم انتظام ضربات القلب، الذبحة الصدرية، موت مفاجئ للقلب.</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية , الدوخة والإسهال بشكل متكرر أكثر في الرجال الذين يتناولون <strong>تادالافيل</strong> بعمر اكبر من 75 سنة.</p><p dir="RTL">اذا أصبح أي من الآثار الجانبية خطيرا, أو إذا لاحظت أي آثار جانبية غير مذكورة في هذه النشرة ، يرجى إخبار الطبيب أو الصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5 </strong><strong>ظروف تخزين ريديكس 5 ملجم</strong></p><p dir="RTL">احفظ الدواء بعيدا عن متناول و نظر الأطفال.</p><p dir="RTL">لا تحفظ الدواء في درجة حرارة أعلى من 30˚م .</p><p dir="RTL">لا تستعمل&nbsp; <strong>ريديكس</strong> 5 ملجم بعد انقضاء تاريخ الصلاحية المدون على علبة الكرتون بعد كلمة Exp. يشير تاريخ الصلاحية الى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">احفظ الدواء في العلبة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">لا ينبغي أن يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن&nbsp; كيفية التخلص من الأدوية التي لم تعد لازمة. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هي محتويات ريديكس 5 ملجم:</strong><br />المادة الفعالة هي تادالافيل. يحتوي كل قرص مغلف على 5 ملجم تادالافيل.&nbsp;</p><p><strong>المكونات الأخرى:</strong> هي لاكتوز وحيد التميه، كاربوكسي ميثيل سليولوز الصوديوم، سليولوز دقيق التبلور، لوريل سلفات الصوديوم، بوفيدون ك 30، ستيرات المغنيسيوم ، أكسيد الحديد الأصفر، و أبادراي 2 أبيض.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هو شكل ريديكس 5 ملجم الصيدلاني و وصفه و حجم عبوته</strong><br />قرص ريديكس 5 ملجم أصفر مغلف غشائيا, لوزي الشكل, محدب الوجهين محفور (TQ) على أحد وجهيه و فارغ على الجانب الآخر.<br />يزود ريديكس 5 ملجم في عبوات سعة 30 قرصا مغلفا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة التقدم للصناعات الدوائية<br />الموقر- عمان, الأردن<br />هاتف: 4050092 -6- 962 + &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;فاكس: &nbsp;4050091 -6- 962 +<br />صندوق بريد: 1019 &nbsp;عمان &nbsp;11947 &nbsp;الأردن<br />البريد الالكتروني: info@tqpharma.com<br />تم الموافقة على هذه النشرة بتاريخ أيلول / 2016 , رقم المراجعة 0<br /><strong>للابلاغ عن أي آثار جانبية:</strong><br />المملكة العربية السعودية<br />المركز الوطني للتيقظ و السلامة الدوائية<br />فاكس: 7662-250-11-966+<br />هاتف: 2038222-11-966+, فرعي: 2317-2356-2353-2354-2334-2340.<br />الهاتف المجاني:8002490000<br />البريد الالكتروني : &nbsp;npc.drug@sfda.gov.sa<br />الموقع الكتروني: www.sfda.gov.sa/npc &nbsp;<br />دول الخليج الأخرى:<br />الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Sep. 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Redex 20, 10 & 5 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The active substance is tadalafil.
Redex 5: Each film coated tablet contains 5 mg of tadalafil.
Redex 10: Each film coated tablet contains 10 mg of tadalafil.
Redex 20: Each film coated tablet contains 20 mg of tadalafil.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Redex is a yellow film coated tablet, almond shaped, biconvex engraved with ''TQ" on one side
and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Therapeutic indications</strong><br />Treatment of erectile dysfunction in adult males.<br />In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is<br />required.<br />5 mg only: Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.<br />REDEX is not indicated for use by women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br /><em>Erectile dysfunction in adult Men</em><br />In general, the recommended dose is 10 mg taken prior to anticipated sexual activity and with or<br />without food.<br />In those patients in whom tadalafil 10 mg does not produce an adequate effect, 20 mg might be<br />tried. It may be taken at least 30 minutes prior to sexual activity.<br />The maximum dose frequency is once per day.<br />Tadalafil 10 and 20 mg is intended for use prior to anticipated sexual activity and it is not<br />recommended for continuous daily use.<br />In patients who anticipate a frequent use of REDEX (i.e., at least twice weekly) a once daily<br />regimen with the lowest doses of REDEX might be considered suitable, based on patient choice<br />and the physician&#39;s judgement.<br />In these patients, the recommended dose is 5mg taken once a day at approximately the same<br />time of day. The dose may be decreased to 2.5mg once a day based on individual tolerability.<br />The appropriateness of continued use of the daily regimen should be reassessed periodically.<br />Benign prostatic hyperplasia in adult men (tadalafil 5 mg only)<br />The recommended dose is 5 mg, taken at approximately the same time every day with or without<br />food. For adult men being treated for both benign prostatic hyperplasia and erectile dysfunction<br />the recommended dose is also 5 mg taken at approximately the same time every day. Patients<br />who are unable to tolerate tadalafil 5 mg for the treatment of benign prostatic hyperplasia should<br />consider an alternative therapy as the efficacy of tadalafil 2.5 mg for the treatment of benign<br />prostatic hyperplasia has not been demonstrated.<br /><u>Special Populations</u><br />Elderly Men<br />Dose adjustments are not required in elderly patients.<br />Men with Renal Impairment<br />Dose adjustments are not required in patients with mild to moderate renal impairment. For<br />patients with severe renal impairment, 10 mg is the maximum recommended dose.<br />Once-a-day dosing of 2.5 or 5 mg tadalafil both for the treatment of erectile dysfunction or benign<br />prostatic hyperplasia is not recommended in patients with severe renal impairment (see sections<br />4.4 and 5.2).<br /><em>Men with Hepatic Impairment</em></p><p>For the treatment of erectile dysfunction using on-demand REDEX the recommended dose of<br />REDEX is 10 mg taken prior to anticipated sexual activity and with or without food. There is<br />limited clinical data on the safety of REDEX in patients with severe hepatic impairment (Child-<br />Pugh class C); if prescribed, a careful individual benefit/risk evaluation should be undertaken by<br />the prescribing physician. There are no available data about the administration of doses higher<br />than 10mg of tadalafil to patients with hepatic impairment.<br />Once-a-day dosing both for the treatment of erectile dysfunction and benign prostatic hyperplasia<br />has not been evaluated in patients with hepatic impairment; therefore, if prescribed, a careful<br />individual benefit/risk evaluation should be undertaken by the prescribing physician (see sections<br />4.4 and 5.2).<br />Men with Diabetes<br />Dose adjustments are not required in diabetic patients.<br />Paediatric population<br />There is no relevant use of REDEX in the paediatric population with regard to the treatment of<br />erectile dysfunction.<br />Method of administration<br />REDEX is available as 2.5, 5, 10, and 20 mg film-coated tablets for oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is
thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP
pathway. Therefore, administration of REDEX to patients who are using any form of organic
nitrate is contraindicated (see section 4.5).
REDEX must not be used in men with cardiac disease for whom sexual activity is inadvisable.
Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing
cardiovascular disease.
The following groups of patients with cardiovascular disease were not included in clinical trials
and the use of tadalafil is therefore contraindicated:
- patients with myocardial infarction within the last 90 days,
- patients with unstable angina or angina occurring during sexual intercourse,
- patients with New York Heart Association Class 2 or greater heart failure in the last 6 months,
- patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled
hypertension,
- patients with a stroke within the last 6 months.
REDEX is contraindicated in patients who have loss of vision in one eye because of non-arteritic
anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in
connection or not with previous PDE5 inhibitor exposure (see section 4.4).
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see
section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment with REDEX<br />A medical history and physical examination should be undertaken to diagnose erectile<br />dysfunction or benign prostatic hyperplasia and determine potential underlying causes, before<br />pharmacological treatment is considered.<br />Prior to initiating any treatment for erectile dysfunction, physicians should consider the<br />cardiovascular status of their patients, since there is a degree of cardiac risk associated with<br />sexual activity. Tadalafil has vasodilator properties, resulting in mild and transient decreases in<br />blood pressure (see section 5.1) and as such potentiates the hypotensive effect of nitrates (see<br />section 4.3).<br />The evaluation of erectile dysfunction should include a determination of potential underlying<br />causes and the identification of appropriate treatment following an appropriate medical</p><p>assessment. It is not known if REDEX is effective in patients who have undergone pelvic surgery<br />or radical non-nerve-sparing prostatectomy.<br />Tadalafil 5 mg - Prior to initiating treatment with tadalafil for benign prostatic hyperplasia patients<br />should be examined to rule out the presence of carcinoma of the prostate and carefully assessed<br />for cardiovascular conditions (see section 4.3).<br />Cardiovascular<br />Serious cardiovascular events, including myocardial infarction, sudden cardiac death, unstable<br />angina pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest pain,<br />palpitations and tachycardia, have been reported either post marketing and/or in clinical trials.<br />Most of the patients in whom these events have been reported had pre-existing cardiovascular<br />risk factors. However, it is not possible to definitively determine whether these events are related<br />directly to these risk factors, to REDEX, to sexual activity, or to a combination of these or other<br />factors.<br />Tadalafil 2.5 mg and 5 mg - In patients receiving concomitant antihypertensive medicinal<br />products, tadalafil may induce a blood pressure decrease. When initiating daily treatment with<br />tadalafil, appropriate clinical considerations should be given to a possible dose adjustment of the<br />antihypertensive therapy.<br />In patients who are taking alpha1 blockers, concomitant administration of REDEX may lead to<br />symptomatic hypotension in some patients (see section 4.5). The combination of tadalafil and<br />doxazosin is not recommended.<br />Vision<br />Visual defects and cases of NAION have been reported in connection with the intake of REDEX<br />and other PDE5 inhibitors. The patient should be advised that in case of sudden visual defect, he<br />should stop taking REDEX and consult a physician immediately (see section 4.3).<br />Renal and hepatic impairment (tadalafil 2.5 mg and 5 mg)<br />Due to increased tadalafil exposure (AUC), limited clinical experience and the lack of ability to<br />influence clearance by dialysis, once-a-day dosing of REDEX is not recommended in patients<br />with severe renal impairment.<br />There is limited clinical data on the safety of single-dose administration of REDEX in patients with<br />severe hepatic insufficiency (Child-Pugh Class C). Once-a-day administration has not been<br />evaluated in patients with hepatic insufficiency. If REDEX is prescribed, a careful individual<br />benefit/risk evaluation should be undertaken by the prescribing physician.<br />Hepatic impairment (tadalafil 10 mg and 20 mg)<br />There is limited clinical data on the safety of single-dose administration of REDEX in patients with<br />severe hepatic insufficiency (Child-Pugh Class C). If REDEX is prescribed, a careful individual<br />benefit/risk evaluation should be undertaken by the prescribing physician.<br />Priapism and anatomical deformation of the penis<br />Patients who experience erections lasting 4 hours or more should be instructed to seek<br />immediate medical assistance. If priapism is not treated immediately, penile tissue damage and<br />permanent loss of potency may result.<br />REDEX, should be used with caution in patients with anatomical deformation of the penis (such<br />as angulation, cavernosal fibrosis, or Peyronie&#39;s disease) or in patients who have conditions<br />which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or<br />leukaemia).</p><p>Use with CYP3A4 inhibitors<br />Caution should be exercised when prescribing REDEX to patients using potent CYP3A4 inhibitors<br />(ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin), as increased tadalafil<br />exposure (AUC) has been observed if the medicinal products are combined (see section 4.5).<br />REDEX and other treatments for erectile dysfunction<br />The safety and efficacy of combinations of REDEX and other PDE5 inhibitors or other treatments<br />for erectile dysfunction have not been studied. The patients should be informed not to take<br />REDEX in such combinations.</p><p>Lactose<br />REDEX contains lactose. Patients with rare hereditary problems of galactose intolerance, the<br />Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal<br />product.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies were conducted with 10 mg and/or 20 mg tadalafil, as indicated below. With<br />regard to those interaction studies where only the 10 mg tadalafil dose was used, clinically<br />relevant interactions at higher doses cannot be completely ruled out.<br />Effects of Other Substances on Tadalafil<br />Cytochrome P450 inhibitors<br />Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole<br />(200 mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and Cmax by 15%, relative to<br />the AUC and Cmax values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20<br />mg) exposure (AUC) 4-fold and Cmax by 22%. Ritonavir, a protease inhibitor (200 mg twice daily),<br />which is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg)<br />exposure (AUC) 2-fold with no change in Cmax. Although specific interactions have not been<br />studied, other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as<br />erythromycin, clarithromycin, itraconazole, and grapefruit juice, should be co-administered with<br />caution, as they would be expected to increase plasma concentrations of tadalafil (see section<br />4.4). Consequently, the incidence of the adverse reactions listed in section 4.8 might be<br />increased.</p><p>Transporters<br />The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not known.<br />Therefore, there is the potential of drug interactions mediated by inhibition of transporters.<br />Cytochrome P450 inducers<br />A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for<br />tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy of<br />tadalafil; the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4, such as<br />phenobarbital, phenytoin, and carbamazepine, may also decrease plasma concentrations of<br />tadalafil.<br />Effects of Tadalafil on Other Medicinal Products<br />Nitrates<br />In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of<br />nitrates. Therefore, administration of REDEX to patients who are using any form of organic nitrate<br />is contraindicated (see section 4.3). Based on the results of a clinical study in which 150 subjects<br />receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various<br />times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours<br />had elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of REDEX (2.5<br />mg- 20 mg), where nitrate administration is deemed medically necessary in a life-threatening<br />situation, at least 48 hours should have elapsed after the last dose of REDEX before nitrate<br />administration is considered. In such circumstances, nitrates should only be administered under<br />close medical supervision with appropriate haemodynamic monitoring.<br />Anti-hypertensives (including calcium channel blockers)<br />The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg<br />as a single dose) increases the blood pressure-lowering effect of this alpha-blocker in a<br />significant manner. This effect lasts at least twelve hours and may be symptomatic, including<br />syncope. Therefore, this combination is not recommended (see section 4.4).<br />In interaction studies performed in a limited number of healthy volunteers, these effects were not<br />reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil<br />in patients treated with any alpha-blockers, and notably in the elderly. Treatments should be<br />initiated at minimal dosage and progressively adjusted.</p><p>In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of<br />antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal<br />products were studied, including calcium-channel blockers (amlodipine), angiotensin converting<br />enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide<br />diuretics (bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or<br />in combination with thiazides, calcium-channel blockers, beta-blockers, and/or alpha-blockers).<br />Tadalafil (10 mg, except for studies with angiotensin II receptor blockers and amlodipine in which<br />a 20 mg dose was applied) had no clinically significant interaction with any of these classes. In<br />another clinical pharmacology study, tadalafil (20 mg) was studied in combination with up to 4<br />classes of antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-bloodpressure<br />changes appeared to relate to the degree of blood pressure control. In this regard, study<br />subjects whose blood pressure was well controlled, the reduction was minimal and similar to that<br />seen in healthy subjects. In study subjects whose blood pressure was not controlled, the<br />reduction was greater, although this reduction was not associated with hypotensive symptoms in<br />the majority of subjects. In patients receiving concomitant antihypertensive medicinal products,<br />tadalafil 20 mg may induce a blood pressure decrease, which (with the exception of alphablockers<br />- see above) is, in general, minor and not likely to be clinically relevant. Analysis of<br />Phase 3 clinical trial data showed no difference in adverse events in patients taking tadalafil with<br />or without antihypertensive medicinal products. However, appropriate clinical advice should be<br />given to patients regarding a possible decrease in blood pressure when they are treated with<br />antihypertensive medicinal products.<br />Riociguat<br />Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5<br />inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment<br />the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of<br />the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors,<br />including tadalafil, is contraindicated (see section 4.3).<br />5- alpha reductase inhibitors<br />In a clinical trial that compared tadalafil 5 mg coadministered with finasteride 5 mg to placebo<br />plus finasteride 5 mg in the relief of BPH symptoms, no new adverse reactions were identified.<br />However, as a formal drug-drug interaction study evaluating the effects of tadalafil and 5-alpha<br />reductase inhibitors (5-ARIs) has not been performed, caution should be exercised when tadalafil<br />is co-administered with 5-ARIs.<br />CYP1A2 substrates (e.g. theophylline)<br />When tadalafil 10 mg was administered with theophylline (a non-selective phosphodiesterase<br />inhibitor) in a clinical pharmacology study, there was no pharmacokinetic interaction. The only<br />pharmacodynamic effect was a small (3.5 bpm) increase in heart rate. Although this effect is<br />minor and was of no clinical significance in this study, it should be considered when coadministering<br />these medicinal products.<br />Ethinylestradiol and terbutaline<br />Tadalafil has been demonstrated to produce an increase in the oral bioavailability of<br />ethinylestradiol; a similar increase may be expected with oral administration of terbutaline,<br />although the clinical consequence of this is uncertain.<br />Alcohol<br />Alcohol concentrations (mean maximum blood concentration 0.08%) were not affected by coadministration<br />with tadalafil (10 mg or 20 mg). In addition, no changes in tadalafil concentrations<br />were seen 3 hours after co-administration with alcohol. Alcohol was administered in a manner to<br />maximise the rate of alcohol absorption (overnight fast with no food until 2 hours after alcohol).<br />Tadalafil (20 mg) did not augment the mean blood pressure decrease produced by alcohol (0.7<br />g/kg or approximately 180 ml of 40% alcohol [vodka] in an 80 kg male) but, in some subjects,<br />postural dizziness and orthostatic hypotension were observed. When tadalafil was administered<br />with lower doses of alcohol (0.6 g/kg), hypotension was not observed and dizziness occurred with</p><p>similar frequency to alcohol alone. The effect of alcohol on cognitive function was not augmented<br />by tadalafil (10 mg).<br />Cytochrome P450 metabolised medicinal products<br />Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of<br />medicinal products metabolised by CYP450 isoforms. Studies have confirmed that tadalafil does<br />not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9<br />and CYP2C19.<br />CYP2C9 substrates (e.g. R-warfarin)<br />Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposure (AUC) to S-warfarin<br />or R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by<br />warfarin.<br />Aspirin<br />Tadalafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by<br />acetylsalicylic acid.<br />Antidiabetic medicinal products<br />Specific interaction studies with antidiabetic medicinal products were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>REDEX is not indicated for use by women.<br />Pregnancy<br />There are limited data from the use of tadalafil in pregnant women. Animal studies do not indicate<br />direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development,<br />parturition or postnatal development (see section 5.3). As a precautionary measure, it is<br />preferable to avoid the use of REDEX during pregnancy.<br />Breastfeeding<br />Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil in<br />milk. A risk to the suckling child cannot be excluded. REDEX should not be used during breast<br />feeding.<br />Fertility<br />Effects were seen in dogs that might indicate impairment of fertility. Two subsequent clinical<br />studies suggest that this effect is unlikely in humans, although a decrease in sperm concentration<br />was seen in some men (see sections 5.1 and 5.3).<br />4.7 Effects on ability to drive and use machines<br />REDEX has negligible influence on the ability to drive or use machines. Although the frequency of<br />reports of dizziness in placebo and tadalafil arms in clinical trials was similar, patients should be<br />aware of how they react to REDEX before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>REDEX has negligible influence on the ability to drive or use machines. Although the frequency of<br />reports of dizziness in placebo and tadalafil arms in clinical trials was similar, patients should be<br />aware of how they react to REDEX before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The most commonly reported adverse reactions in patients taking REDEX for the treatment of<br />erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and<br />myalgia, in which the incidences increase with increasing dose of REDEX. The adverse reactions<br />reported were transient, and generally mild or moderate. The majority of headaches reported with<br />REDEX once-a-day dosing are experienced within the first 10 to 30 days of starting treatment.<br />Tabulated summary of adverse reactions<br />The table below lists the adverse reactions observed from spontaneous reporting and in placebocontrolled<br />clinical trials (comprising a total of 8022 patients on REDEX and 4422 patients on<br />placebo) for on-demand and once-a-day treatment of erectile dysfunction and the once-a-day<br />treatment of benign prostatic hyperplasia.<br />Frequency convention: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000<br />to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000) and Not known (cannot be<br />estimated from the available data).</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:836px"><tbody><tr><td style="text-align:center; width:170px">Very common</td><td style="text-align:center; width:209px">&nbsp;Common &nbsp;</td><td style="text-align:center; width:210px">Uncommon&nbsp;</td><td style="text-align:center; width:246px"><p>Rare&nbsp;</p></td></tr><tr><td colspan="4" style="width:170px">Immune system disorders</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">&nbsp;</td><td style="width:210px">Hypersensitivity reactions</td><td style="width:246px">Angioedema<sup>2</sup></td></tr><tr><td colspan="4" style="width:170px">Nervous system disorders</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">Headache</td><td style="width:210px">Dizziness</td><td style="width:246px">Stroke<sup>1</sup> (including haemorrhagic events), Syncope, Transient ischaemic attacks<sup>1</sup>, Migraine<sup>2</sup>, Seizures<sup>2</sup>, Transient amnesia</td></tr><tr><td style="width:170px">Eye disorders</td><td rowspan="1" colspan="3" style="width:209px">&nbsp;</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">&nbsp;</td><td style="width:210px">Blurred vision, Sensations described as eye pain</td><td style="width:246px">Visual field defect, Swelling of eyelids, Conjunctival hyperaemia, Non-arteritic anterior ischaemic optic neuropathy (NAION)<sup>2</sup>, Retinal vascular occlusion<sup>2</sup></td></tr><tr><td style="width:170px">Ear and labyrinth disorders</td><td rowspan="1" colspan="3" style="width:209px">&nbsp;</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">&nbsp;</td><td style="width:210px">Tinnitus</td><td style="width:246px">Sudden hearing loss</td></tr><tr><td colspan="4" style="width:170px">Cardiac disorders1</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">&nbsp;</td><td style="width:210px">Tachycardia, Palpitations</td><td style="width:246px">Myocardial infarction, Unstable angina pectoris<sup>2</sup>, Ventricular arrhythmia<sup>2</sup></td></tr><tr><td rowspan="1" colspan="3" style="width:170px">Vascular disorders</td><td style="width:246px">&nbsp;</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">Flushing</td><td style="width:210px">Hypotension<sup>3</sup>, Hypertension</td><td style="width:246px">&nbsp;</td></tr><tr><td rowspan="1" colspan="3" style="width:170px">Respiratory, thoracic and mediastinal disorders</td><td style="width:246px">&nbsp;</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">Nasal congestion</td><td style="width:210px">Dyspnoea, Epistaxis</td><td style="width:246px">&nbsp;</td></tr><tr><td rowspan="1" colspan="3" style="width:170px">Gastrointestinal disorders</td><td style="width:246px">&nbsp;</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">Dyspepsia</td><td style="width:210px">Abdominal pain, Vomiting, Nausea, Gastrooesophageal reflux</td><td style="width:246px">&nbsp;</td></tr><tr><td rowspan="1" colspan="3" style="width:170px">Skin and subcutaneous tissue disorders</td><td style="width:246px">&nbsp;</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">&nbsp;</td><td style="width:210px">Rash</td><td style="width:246px">Urticaria, Stevens-Johnson syndrome<sup>2</sup>, Exfoliative dermatitis<sup>2</sup>, Hyperhydrosis (sweating)</td></tr><tr><td rowspan="1" colspan="3" style="width:170px">Musculoskeletal, connective tissue and bone disorders</td><td style="width:246px">&nbsp;</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">Back pain, Myalgia, Pain in<br />extremity</td><td style="width:210px">&nbsp;</td><td style="width:246px">&nbsp;</td></tr><tr><td colspan="4" style="width:170px">Renal and urinary disorders</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">&nbsp;</td><td style="width:210px">Haematuria</td><td style="width:246px">&nbsp;</td></tr><tr><td colspan="4" style="width:170px">Reproductive system and breast disorders</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:209px">&nbsp;</td><td style="width:210px">Prolonged erections</td><td style="width:246px">Priapism, Penile haemorrhage, Haematospermia</td></tr><tr><td colspan="4" style="width:170px">General disorders and administration site conditions</td></tr><tr><td style="width:170px">&nbsp;</td><td style="width:170px">&nbsp;</td><td style="width:170px">Chest pain<sup>1</sup>, Peripheral oedema, Fatigue</td><td style="width:170px">Facial oedema<sup>2</sup>, Sudden cardiac death<sup>1,2</sup></td></tr></tbody></table><p>(1) Most of the patients had pre-existing cardiovascular risk factors (see section 4.4).<br />(2) Postmarketing surveillance reported adverse reactions not observed in placebo-controlled<br />clinical trials.<br />(3) More commonly reported when tadalafil is given to patients who are already taking<br />antihypertensive medicinal products.<br />Description of selected adverse reactions<br />A slightly higher incidence of ECG abnormalities, primarily sinus bradycardia, has been reported<br />in patients treated with tadalafil once a day as compared with placebo. Most of these ECG<br />abnormalities were not associated with adverse reactions.<br />Other special populations<br />Data in patients over 65 years of age receiving tadalafil in clinical trials, either for the treatment of<br />erectile dysfunction or the treatment of benign prostatic hyperplasia, are limited. In clinical trials<br />with tadalafil taken on demand for the treatment of erectile dysfunction, diarrhoea was reported<br />more frequently in patients over 65 years of age. In clinical trials with tadalafil 5 mg taken once a<br />day for the treatment of benign prostatic hyperplasia, dizziness and diarrhoea were reported more<br />frequently in patients over 75 years of age.<br /><strong>Reporting of suspected adverse reactions</strong><br />To report any side effects(s):<br />Saudi Arabia:<br />National Pharmacovigilance and Drug Safety Center (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />Email: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />Other GCC States: Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses of up to 500 mg have been given to healthy subjects, and multiple daily doses up to<br />100 mg have been given to patients. Adverse events were similar to those seen at lower doses.<br />In cases of overdose, standard supportive measures should be adopted, as required.<br />Haemodialysis contributes negligibly to tadalafil elimination.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction. ATC code:<br />G04BE08.<br />Mechanism of action<br />Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific<br />phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric<br />oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus<br />cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues,<br />thereby producing an erection. Tadalafil has no effect in the treatment of erectile dysfunction in<br />the absence of sexual stimulation.<br />Tadalafil 5 mg - The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum<br />is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The<br />resulting vascular relaxation increases blood perfusion which may be the mechanism by which<br />symptoms of benign prostatic hyperplasia are reduced. These vascular effects may be<br />complemented by inhibition of bladder afferent nerve activity and smooth muscle relaxation of the<br />prostate and bladder.</p><p>Pharmacodynamic effects<br />Studies in vitro have shown that tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme<br />found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle, skeletal<br />muscle, platelets, kidney, lung, and cerebellum. The effect of tadalafil is more potent on PDE5<br />than on other phosphodiesterases. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE1,<br />PDE2, and PDE4 enzymes which are found in the heart, brain, blood vessels, liver, and other<br />organs. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the<br />heart and blood vessels. This selectivity for PDE5 over PDE3 is important because PDE3 is an<br />enzyme involved in cardiac contractility. Additionally, tadalafil is approximately 700-fold more<br />potent for PDE5 than for PDE6, an enzyme which is found in the retina and is responsible for<br />phototransduction. Tadalafil is also &gt;10,000-fold more potent for PDE5 than for PDE7 through<br />PDE10.<br />Clinical efficacy and safety<br />Tadalafil administered to healthy subjects produced no significant difference compared to placebo<br />in supine systolic and diastolic blood pressure (mean maximal decrease of 1.6/0.8mmHg,<br />respectively), in standing systolic and diastolic blood pressure (mean maximal decrease of<br />0.2/4.6mmHg, respectively), and no significant change in heart rate.<br />In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination<br />(blue/green) was detected using the Farnsworth-Munsell 100-hue test. This finding is consistent<br />with the low affinity of tadalafil for PDE6 compared to PDE5. Across all clinical studies, reports of<br />changes in colour vision were rare (&lt;0.1%).<br />Three studies were conducted in men to assess the potential effect on spermatogenesis of<br />REDEX 10mg (one 6-month study) and 20mg (one 6-month and one 9-month study)<br />administered daily. In two of these studies decreases were observed in sperm count and<br />concentration related to tadalafil treatment of unlikely clinical relevance. These effects were not<br />associated with changes in other parameters, such as motility, morphology, and FSH.<br />Erectile dysfunction<br />Three clinical studies were conducted in 1054 patients in an at-home setting to define the period<br />of responsiveness to REDEX on demand. Tadalafil demonstrated statistically significant<br />improvement in erectile function and the ability to have successful sexual intercourse up to 36<br />hours following dosing, as well as patients&#39; ability to attain and maintain erections for successful<br />intercourse compared to placebo as early as 16 minutes following dosing.<br />In a 12-week study performed in 186 patients (142 tadalafil, 44 placebo) with erectile dysfunction<br />secondary to spinal cord injury, tadalafil significantly improved the erectile function leading to a<br />mean per-subject proportion of successful attempts in patients treated with tadalafil 10 or 20 mg<br />(flexible-dose, on demand) of 48% as compared to 17% with placebo.<br />Tadalafil at doses of 2 to 100mg has been evaluated in 16 clinical studies involving 3250 patients,<br />including patients with erectile dysfunction of various severities (mild, moderate, severe),<br />etiologies, ages (range 21-86 years), and ethnicities. Most patients reported erectile dysfunction<br />of at least 1 year in duration. In the primary efficacy studies of general populations, 81% of<br />patients reported that REDEX improved their erections as compared to 35% with placebo. Also,<br />patients with erectile dysfunction in all severity categories reported improved erections whilst<br />taking REDEX (86%, 83%, and 72% for mild, moderate, and severe, respectively, as compared to<br />45%, 42%, and 19% with placebo). In the primary efficacy studies, 75% of intercourse attempts<br />were successful in REDEX-treated patients as compared to 32% with placebo.<br />For once-a-day evaluation of tadalafil at doses of 2.5, 5, and 10 mg 3 clinical studies were initially<br />conducted involving 853 patients of various ages (range 21-82 years) and ethnicities, with erectile<br />dysfunction of various severities (mild, moderate, severe) and etiologies. In the two primary<br />efficacy studies of general populations, the mean per-subject proportion of successful intercourse<br />attempts were 57 and 67% on REDEX 5mg, 50% on REDEX 2.5mg as compared to 31 and 37%<br />with placebo. In the study in patients with erectile dysfunction secondary to diabetes, the mean<br />per-subject proportion of successful attempts were 41 and 46% on REDEX 5mg and 2.5mg,</p><p>respectively, as compared to 28% with placebo. Most patients in these three studies were<br />responders to previous on-demand treatment with PDE5 inhibitors. In a subsequent study, 217<br />patients who were treatment-naive to PDE5 inhibitors were randomised to REDEX 5mg once a<br />day vs. placebo. The mean per-subject proportion of successful sexual intercourse attempts was<br />68% for REDEX patients compared to 52% for patients on placebo.<br />Benign prostatic hyperplasia<br />REDEX was studied in 4 clinical studies of 12 weeks duration enrolling over 1500 patients with<br />signs and symptoms of benign prostatic hyperplasia. The improvement in the total international<br />prostate symptom score with REDEX 5mg in the four studies were -4.8, -5.6, -6.1 and -6.3<br />compared to -2.2, -3.6, -3.8 and -4.2 with placebo. The improvements in total international<br />prostate symptom score occurred as early as 1 week. In one of the studies, which also included<br />tamsulosin 0.4 mg as an active comparator, the improvement in total international prostate<br />symptom score with REDEX 5mg, tamsulosin and placebo were -6.3, -5.7 and -4.2 respectively.<br />One of these studies assessed improvements in erectile dysfunction and signs and symptoms of<br />benign prostatic hyperplasia in patients with both conditions. The improvements in the erectile<br />function domain of the international index of erectile function and the total international prostate<br />symptom score in this study were 6.5 and -6.1 with REDEX 5 mg compared to 1.8 and -3.8 with<br />placebo, respectively. The mean per-subject proportion of successful sexual intercourse attempts<br />was 71.9% with REDEX 5 mg compared to 48.3% with placebo.<br />The maintenance of the effect was evaluated in an open-label extension to one of the studies,<br />which showed that the improvement in total international prostate symptom score seen at 12<br />weeks was maintained for up to 1 additional year of treatment with REDEX 5mg.<br />Paediatric population<br />The European Medicines Agency has waived the obligation to submit the results of studies in all<br />subsets of the paediatric population in the treatment of the erectile dysfunction. See section 4.2<br />for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Tadalafil is readily absorbed after oral administration and the mean maximum observed plasma<br />concentration (Cmax) is achieved at a median time of 2 hours after dosing. Absolute bioavailability<br />of tadalafil following oral dosing has not been determined.<br />The rate and extent of absorption of tadalafil are not influenced by food, thus REDEX may be<br />taken with or without food. The time of dosing (morning versus evening) had no clinically relevant<br />effects on the rate and extent of absorption.<br />Distribution<br />The mean volume of distribution is approximately 63 l, indicating that tadalafil is distributed into<br />tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins. Protein<br />binding is not affected by impaired renal function.<br />Less than 0.0005% of the administered dose appeared in the semen of healthy subjects.<br />Biotransformation<br />Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4 isoform. The major<br />circulating metabolite is the methylcatechol glucuronide. This metabolite is at least 13,000-fold<br />less potent than tadalafil for PDE5. Consequently, it is not expected to be clinically active at<br />observed metabolite concentrations.<br />Elimination<br />The mean oral clearance for tadalafil is 2.5 l/h and the mean half-life is 17.5 hours in healthy<br />subjects.<br />Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces (approximately<br />61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).<br />Linearity/Non-Linearity</p><p>Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and dose. Over a<br />dose range of 2.5 to 20 mg, exposure (AUC) increases proportionally with dose. Steady-state<br />plasma concentrations are attained within 5 days of once daily dosing.<br />Pharmacokinetics determined with a population approach in patients with erectile dysfunction are<br />similar to pharmacokinetics in subjects without erectile dysfunction.<br />Special Populations<br />Elderly<br />Healthy elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in<br />25% higher exposure (AUC) relative to healthy subjects aged 19 to 45 years. This effect of age is<br />not clinically significant and does not warrant a dose adjustment.<br />Renal Insufficiency<br />In clinical pharmacology studies using single dose tadalafil (5 to 20mg), tadalafil exposure (AUC)<br />approximately doubled in subjects with mild (creatinine clearance 51 to 80 ml/min) or moderate<br />(creatinine clearance 31 to 50 ml/min) renal impairment and in subjects with end-stage renal<br />disease on dialysis. In haemodialysis patients, Cmax was 41% higher than that observed in healthy<br />subjects. Haemodialysis contributes negligibly to tadalafil elimination.<br />Hepatic Insufficiency<br />Tadalafil exposure (AUC) in subjects with mild and moderate hepatic impairment (Child-Pugh<br />class A and B) is comparable to exposure in healthy subjects when a dose of 10 mg is<br />administered. There is limited clinical data on the safety of REDEX in patients with severe hepatic<br />insufficiency (Child-Pugh class C). If REDEX is prescribed, a careful individual benefit/risk<br />evaluation should be undertaken by the prescribing physician. There are no available data about<br />the administration of once-a-day dosing of tadalafil to patients with hepatic impairment. If REDEX<br />is prescribed once-a-day, a careful individual benefit/risk evaluation should be undertaken by the<br />prescribing physician. There are no available data about the administration of doses higher than<br />10 mg of tadalafil to patients with hepatic impairment.<br />Patients with Diabetes<br />Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC<br />value for healthy subjects. This difference in exposure does not warrant a dose adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to<br />reproduction.<br />There was no evidence of teratogenicity, embryotoxicity, or foetotoxicity in rats or mice that<br />received up to 1000 mg/kg/day tadalafil. In a rat prenatal and postnatal development study, the<br />no observed effect dose was 30 mg/kg/day. In the pregnant rat the AUC for calculated free drug<br />at this dose was approximately 18-times the human AUC at a 20 mg dose.<br />There was no impairment of fertility in male and female rats. In dogs given tadalafil daily for 6 to<br />12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7-<br />18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the<br />seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs.<br />See also section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate<br />Croscarmellose Sodium<br />Microcrystalline Cellulose<br />Sodium Lauryl sulfate<br />Povidone K30<br />Magnesium Stearate<br />Yellow Iron Oxide<br />Opadry II white.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Redex 5 is supplied in 3 blisters packs of 30 film coated tablets.<br />Redex 10, 20 is supplied in blister packs of 2 or 5 film coated tablets.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Al-Taqaddom Pharmaceutical Industries.
Almwaqqar – Amman, Jordan
Tel.: +962-6-4050092
Fax: +962-6-4050091
P.O. Box: 1019 Amman 11947 Jordan
Email: info@tqpharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>